UPDATE - Canaccord Genuity Initiates Coverage on Tranzyme (TZYM) with a Buy; Moving Right Along Into Phase 3 Development
Tweet Send to a Friend
UPDATE - Canaccord Genuity initiates coverage on Tranzyme (NASDAQ: TZYM) with a Buy. PT $7.
Canaccord analyst says, "Initiating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Initiating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
